BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 19553543)

  • 21. HLA-DM and the MHC class II antigen presentation pathway.
    Jensen PE; Weber DA; Thayer WP; Chen X; Dao CT
    Immunol Res; 1999; 20(3):195-205. PubMed ID: 10741860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
    Carstens C; Newman DK; Bohlen H; König A; Koch N
    Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Herpes simplex virus type 1 targets the MHC class II processing pathway for immune evasion.
    Neumann J; Eis-Hübinger AM; Koch N
    J Immunol; 2003 Sep; 171(6):3075-83. PubMed ID: 12960333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamics of major histocompatibility complex class II compartments during B cell receptor-mediated cell activation.
    Lankar D; Vincent-Schneider H; Briken V; Yokozeki T; Raposo G; Bonnerot C
    J Exp Med; 2002 Feb; 195(4):461-72. PubMed ID: 11854359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amino acid substitutions in the putative MHC class II "dimer of dimers" interface inhibit CD4+ T cell activation.
    Lindstedt R; Monk N; Lombardi G; Lechler R
    J Immunol; 2001 Jan; 166(2):800-8. PubMed ID: 11145653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural insights into human MHC-II association with invariant chain.
    Wang N; Waghray D; Caveney NA; Jude KM; Garcia KC
    Proc Natl Acad Sci U S A; 2024 May; 121(19):e2403031121. PubMed ID: 38687785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of acid ceramidase regulates MHC class II antigen presentation and suppression of autoimmune arthritis.
    Zhao D; Hajiaghamohseni LM; Liu X; Szulc ZM; Bai A; Bielawska A; Norris JS; Reddy SV; Hannun YA; Haque A
    Cytokine; 2020 Nov; 135():155219. PubMed ID: 32738771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human B lymphoblastoid cells contain distinct patterns of cathepsin activity in endocytic compartments and regulate MHC class II transport in a cathepsin S-independent manner.
    Lautwein A; Kraus M; Reich M; Burster T; Brandenburg J; Overkleeft HS; Schwarz G; Kammer W; Weber E; Kalbacher H; Nordheim A; Driessen C
    J Leukoc Biol; 2004 May; 75(5):844-55. PubMed ID: 14966190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct endosomal trafficking requirements for presentation of autoantigens and exogenous lipids by human CD1d molecules.
    Chen X; Wang X; Keaton JM; Reddington F; Illarionov PA; Besra GS; Gumperz JE
    J Immunol; 2007 May; 178(10):6181-90. PubMed ID: 17475845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cathepsin S activity regulates antigen presentation and immunity.
    Riese RJ; Mitchell RN; Villadangos JA; Shi GP; Palmer JT; Karp ER; De Sanctis GT; Ploegh HL; Chapman HA
    J Clin Invest; 1998 Jun; 101(11):2351-63. PubMed ID: 9616206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C virus-mediated inhibition of cathepsin S increases invariant-chain expression on hepatocyte surface.
    Kim H; Mazumdar B; Bose SK; Meyer K; Di Bisceglie AM; Hoft DF; Ray R
    J Virol; 2012 Sep; 86(18):9919-28. PubMed ID: 22761382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation.
    Hegde NR; Tomazin RA; Wisner TW; Dunn C; Boname JM; Lewinsohn DM; Johnson DC
    J Virol; 2002 Nov; 76(21):10929-41. PubMed ID: 12368336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
    Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
    J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
    Ramachandra L; Kovats S; Eastman S; Rudensky AY
    J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
    Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
    J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice.
    Nakagawa TY; Brissette WH; Lira PD; Griffiths RJ; Petrushova N; Stock J; McNeish JD; Eastman SE; Howard ED; Clarke SR; Rosloniec EF; Elliott EA; Rudensky AY
    Immunity; 1999 Feb; 10(2):207-17. PubMed ID: 10072073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intestinal epithelial cells use two distinct pathways for HLA class II antigen processing.
    Hershberg RM; Framson PE; Cho DH; Lee LY; Kovats S; Beitz J; Blum JS; Nepom GT
    J Clin Invest; 1997 Jul; 100(1):204-15. PubMed ID: 9202073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of decreasing the affinity of the class II-associated invariant chain peptide on the MHC class II peptide repertoire in the presence or absence of H-2M.
    Honey K; Forbush K; Jensen PE; Rudensky AY
    J Immunol; 2004 Apr; 172(7):4142-50. PubMed ID: 15034026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
    Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
    Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
    Novellino L; Renkvist N; Rini F; Mazzocchi A; Rivoltini L; Greco A; Deho P; Squarcina P; Robbins PF; Parmiani G; Castelli C
    J Immunol; 2003 Jun; 170(12):6363-70. PubMed ID: 12794170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.